| Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non–small-cell lung cancer M Fukuoka, S Yano, G Giaccone, T Tamura, K Nakagawa, JY Douillard, ... Journal of clinical oncology 21 (12), 2237-2246, 2003 | 3993 | 2003 |
| Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised … B Burtness, KJ Harrington, R Greil, D Soulières, M Tahara, G de Castro, ... The Lancet 394 (10212), 1915-1928, 2019 | 2837 | 2019 |
| PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma MR Migden, D Rischin, CD Schmults, A Guminski, A Hauschild, KD Lewis, ... New England Journal of Medicine 379 (4), 341-351, 2018 | 1434 | 2018 |
| Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five … J Baselga, D Rischin, M Ranson, H Calvert, E Raymond, DG Kieback, ... Journal of clinical oncology 20 (21), 4292-4302, 2002 | 1025 | 2002 |
| Prognostic Significance of p16INK4A and Human Papillomavirus in Patients With Oropharyngeal Cancer Treated on TROG 02.02 Phase III Trial D Rischin, RJ Young, R Fisher, SB Fox, QT Le, LJ Peters, B Solomon, ... Journal of clinical oncology 28 (27), 4142-4148, 2010 | 901 | 2010 |
| Critical impact of radiotherapy protocol compliance and quality in the treatment of advanced head and neck cancer: results from TROG 02.02 LJ Peters, B O'Sullivan, J Giralt, TJ Fitzgerald, A Trotti, J Bernier, J Bourhis, ... Journal of clinical oncology 28 (18), 2996-3001, 2010 | 869 | 2010 |
| Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition J Albanell, F Rojo, S Averbuch, A Feyereislova, JM Mascaro, R Herbst, ... Journal of Clinical Oncology 20 (1), 110-124, 2002 | 648 | 2002 |
| Prognostic Significance of [18F]-Misonidazole Positron Emission Tomography–Detected Tumor Hypoxia in Patients With Advanced Head and Neck Cancer … D Rischin, RJ Hicks, R Fisher, D Binns, J Corry, S Porceddu, LJ Peters Journal of Clinical Oncology 24 (13), 2098-2104, 2006 | 606 | 2006 |
| Positron emission tomography is superior to computed tomography scanning for response-assessment after radical radiotherapy or chemoradiotherapy in patients with non–small-cell … MP Mac Manus, RJ Hicks, JP Matthews, A McKenzie, D Rischin, ... Journal of Clinical Oncology 21 (7), 1285-1292, 2003 | 530 | 2003 |
| Head and neck squamous cell carcinoma: Genomics and emerging biomarkers for immunomodulatory cancer treatments B Solomon, RJ Young, D Rischin Seminars in cancer biology 52, 228-240, 2018 | 450 | 2018 |
| Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial MR Migden, NI Khushalani, ALS Chang, KD Lewis, CD Schmults, ... The lancet oncology 21 (2), 294-305, 2020 | 447 | 2020 |
| Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck JSW Stewart, EEW Cohen, L Licitra, CML Van Herpen, C Khorprasert, ... Journal of clinical oncology 27 (11), 1864-1871, 2009 | 446 | 2009 |
| Tirapazamine, cisplatin, and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck (TROG 02.02, HeadSTART): a phase III trial of … D Rischin, LJ Peters, B O'Sullivan, J Giralt, R Fisher, K Yuen, A Trotti, ... Journal of Clinical Oncology 28 (18), 2989-2995, 2010 | 430 | 2010 |
| Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors SN Holden, SG Eckhardt, R Basser, R De Boer, D Rischin, M Green, ... Annals of Oncology 16 (8), 1391-1397, 2005 | 347 | 2005 |
| Survival with cemiplimab in recurrent cervical cancer KS Tewari, BJ Monk, I Vergote, A Miller, AC de Melo, HS Kim, YM Kim, ... New England Journal of Medicine 386 (6), 544-555, 2022 | 328 | 2022 |
| Utility of positron emission tomography for the detection of disease in residual neck nodes after (chemo) radiotherapy in head and neck cancer SV Porceddu, E Jarmolowski, RJ Hicks, R Ware, LA Weih, D Rischin, ... Head & Neck: Journal for the Sciences and Specialties of the Head and Neck …, 2005 | 308 | 2005 |
| Tirapazamine, cisplatin, and radiation versus fluorouracil, cisplatin, and radiation in patients with locally advanced head and neck cancer: a randomized phase II trial of the … D Rischin, L Peters, R Fisher, A Macann, J Denham, M Poulsen, ... Journal of Clinical Oncology 23 (1), 79-87, 2005 | 297 | 2005 |
| Activity of gemcitabine in patients with advanced ovarian cancer: responses seen following platinum and paclitaxel JD Shapiro, MJ Millward, D Rischin, M Michael, V Walcher, PA Francis, ... Gynecologic oncology 63 (1), 89-93, 1996 | 296 | 1996 |
| The ‘QUAD SHOT’—a phase II study of palliative radiotherapy for incurable head and neck cancer J Corry, LJ Peters, I D'Costa, AD Milner, H Fawns, D Rischin, S Porceddu Radiotherapy and oncology 77 (2), 137-142, 2005 | 280 | 2005 |
| F‐18 fluorodeoxyglucose positron emission tomography staging in radical radiotherapy candidates with nonsmall cell lung carcinoma: powerful correlation with survival and high … MP Mac Manus, RJ Hicks, DL Ball, V Kalff, JP Matthews, E Salminen, ... Cancer 92 (4), 886-895, 2001 | 280 | 2001 |
